Compare Adaptive Biotechnologies Corp (ADPT) vs Prudential PLC (PUK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Prudential PLC — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Prudential PLC trades at $27.33 (market cap $33.92B). The key difference: Prudential PLC is far larger — about 10.2× Adaptive Biotechnologies Corp's market cap, and Prudential PLC pays a 1.92% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PUK | |
|---|---|---|
Market Cap | $3.33B | $33.92B |
Sector | Health | Financials |
52-Week High | $22.37 | $33.61 |
52-Week Low | $10.24 | $24.65 |
Enterprise Value | $3.19B | $35.36B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Prudential PLC (PUK) trades at $27.65, up 0.33% today, with a bullish technical outlook and strong fundamentals including a 14.52% net income margin and 21.15% ROE. Recent earnings beat expectations in Q2 and Q4 2025, though Q4 2024 missed. The company shows robust cash flow growth, with operating cash flow reaching $3.61B in 2024, and strategic moves like the Bharti Life Insurance acquisition signal expansion intent. Analyst consensus is mixed but leans positive with 50% buy ratings.
The stock presents a value opportunity with a low P/E of 9.16, but faces risks from regulatory challenges in Japan and market volatility. Upside potential is supported by earnings growth and institutional confidence, though investors should monitor Japan's sales suspension impact and competitive pressures in insurance markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
